CLEC4C Antibodies

C-type lectin domain family 4 member C (CLEC4C)

Lectin-type cell surface receptor which might play a role in antigen shooting by dendritic cells (PubMed:11748283, PubMed:21880719, PubMed:25995448). Specifically recognizes non- sialylated galactose-terminated biantennary glycans containing the trisaccharide epitope Gal(beta1-3/4)GlcNAc(beta1-2)Man (PubMed:21880719, PubMed:25995448).

Binds to serum IgG (PubMed:25995448). Efficiently targets ligand into antigen- processing and peptide-loading compartments for presentation to T- cells (PubMed:11748283).

Gene Information

Human
Gene Name:	CLEC4C
Uniprot:	Q8WTT0
Entrez:	170482

Family

Belongs to:
No superfamily

Alternative Names

BDCA2; BDCA-2; BDCA2MGC125791; blood dendritic cell antigen 2 protein; Blood dendritic cell antigen 2; CD303 antigen; CD303; CLEC4C; CLECSF11; CLECSF11PRO34150; CLECSF7; C-type (calcium dependent, carbohydrate-recognition domain) lectin, superfamilymember 11; C-type (calcium dependent, carbohydrate-recognition domain) lectin, superfamilymember 7; C-type lectin domain family 4 member C; C-type lectin superfamily member 7; dendritic cell lectin b; Dendritic lectin; DLEC; DLECMGC125792; HECL; HECLMGC125793; MGC125789; PRO34150

Molecular Weight

Mass (kDA):
25.038 kDA

Genomic Context

Human
Location:	12p13.31
Sequence:	12; NC_000012.12 (7729245..7751600, complement)

Tissue Specificity

Expressed in plasmacytoid dendritic cells (PDCs). Constitutively expressed in immature monocyte-derived dendritic cells (iMDDC) and is significantly down-regulated upon maturation with LPS but not with TNF-alpha.

Subcellular Localizations

Cell membrane; Single-pass type II membrane protein.

Diseases

• Neoplasms
• Skin Neoplasms
• Lupus Erythematosus, Systemic
• Autoimmune Reaction
• Lymphoma
• Autoimmune Diseases
• Hiv Infections
• Malignant Neoplasms
• Carcinoma
• Inflammation
• Leukemia
• Hepatitis
• Malignant Paraganglionic Neoplasm

• Leukemia, Myelocytic, Acute
• Acute Lymphocytic Leukemia
• Psoriasis
• Malignant Squamous Cell Neoplasm
• Virus Diseases
• Melanoma
• Hepatitis B

Pathways

• Secretion
• Immune Response
• Pathogenesis
• Cell Activation
• Cell Proliferation
• Endocytosis
• Cytokine Production
• Innate Immune Response
• Localization
• Clathrin-mediated Endocytosis
• Dendritic Cell Proliferation
• T Cell Activation

• Adaptive Immune Response
• Reverse Transcription
• Phagocytosis
• Axon Guidance
• T Cell Proliferation
• Plasmacytoid Dendritic Cell Activation
• Trail Production

PTMs

• Phosphorylation

• Ubiquitination

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/CLEC4C

Best Uses Of The CLEC4C Marker

When looking for a CLEC4C antibody, consider Wuhan Boster Biological Technology, Ltd. These biotechnological companies specialize in high-sensitivity ELISA kit and compatible WB/IHC antibodies. Steven Xia founded these biotechnological firms in 1993. He has spent more than two decades perfecting his methods. Boster Bio's antibodies have been published in more than 29,000 publications.

Immun

A "marker" is a gene which is expressed by T cell lymphocytes in immunology. A marker sequence can be accompanied by either a symbol (a "+") or a symbol (a "-" symbol). This identifies which cell type expresses the antigen. Typically, T cell markers are present on regulatory, helper and killer T cells. Recent discoveries in immunology challenge previously accepted ideas.

Immunomodulators

The CLEC4C marker can be used to identify human pDCs. It could also be used as an alternative method to determine the number of pDCs in human samples. CLEC4C gene activity is highly variable and it is impossible to detect all the cells in a human specimen. RTPCR can however detect CLEC4C genes in human samples. This makes CLEC4C gene encoding a promising alternative to RT-PCR for quantitating the number pDCs in a patient sample.

Adjuvants

The CLEC4C ligand is expressed on surface molecules of tumor cells. The pDC reaction is inhibited by CLEC4C receptors. This could have clinical implications. CLEC4CCRD-PE binding to Jurkat cells (human tumor cell lines) and CLEC4C4C-CRD–PE bound to Jurkat cell lines. Jurkat cells are immortalized human T cells from patients diagnosed with T cell Leukemia. However, the ligand failed to bind to freshly isolated lymphocytes.

CLEC4CCRD-PE binding was studied. It showed that oligosaccharides with terminal galactose, b1-4-galactose, and other oligosaccharides were highly binding to monocytes. Furthermore, the CLEC4C-CRD-PE molecule was not significantly reduced by the addition of b-(1-4)-galactosidase. This result suggests that the b1-3-galactose residues are critical for CLEC4C-CRD-PE binding.

To test if CLEC4C ligands would bind to selected leukocyte populations, fluorescent tetramers were used. CLEC4C–CRD–PE bound to purified CD14+ and monocyte–derived dritic cells at a rate of 50%. The binding of anti-CLEC4C antibodies inhibited, but the binding ability of CLEC4C–CRD-PE ligand-binding antibody was not affected by the isotype-matched antibody. The ligand did NOT bind with CD14-positive peripheral Blood mononocytes (which also include T and lymphocytes), natural Killer Cells (NK), and EBV transformed B cells.

Although adjuvants are used to enhance vaccine immunogenicity almost a century ago, selecting the right adjuvant to improve a vaccine formulation is a complicated task. The choice of adjuvants can stimulate both cell-mediated as well as humoral immunity. Historically, adjuvant selection has been empirical, but recent advances in immunology and vaccine development make it possible to rationally select the best adjuvant. Although there are few adjuvants currently licensed, there are many in clinical trials. They are expected to be approved soon. Adjuvant selection plays an important role in rationalizing vaccines and adjuvants.

ELISA kits

Boster Bio is a company that develops and manufactures ELISA kits and antibodies. They target biomarkers such as cancer, neurosciences or developmental biology. Their products are extremely sensitive and specific with picogram levels. Boster Bio ELISA products can be purchased via tebu.bio. These kits provide high-quality antibodies and have been tested against 250 human tissue samples.

CLEC4C (a protein with a predicted amino acid length (213) and a mass of 25kDa is CLEC4C. This protein is found in various animal samples, and many biological assays rely on antibodies to detect the protein. Boster Bio uses mouse and rabbit as models to develop its CLEC4C ELISA kit. CLEC4C is a calcium-dependent carbohydrate-recognition domain found on dendritic cells. High reproducibility is a hallmark in ELISA kit for CLEC4C.

WB/IHC compatible antibodies

Wuhan Boster Biological Technology, Ltd. is a company that produces WB/IHC compatible antibody and high-sensitivity ELISA kit kits. They have been perfecting their methods for over 20 years. Their antibodies have been validated for Western blot (ELISA) and flow cytometry. They also offer a free secondary antibody with every order. They can help your lab find the perfect complement, no matter if you're looking to purchase a single or a collection of antibodies.

CLEC4C samples must be kept at -20°C or -80°C in liquid nitrogen. Boster Bio does no routinely validate tissue homogenates. However, you can preserve the stability of your samples by dividing the samples into single-use quantities and freezing them to reduce protein degradation. Routine use can be made of samples that can sustain linearity and recovery rates between 80-120%.

Samples containing CLEC4C should be pretreated before they are used in a WB/IHC compliant method. To prepare a sample for immunohistochemistry, use Boster's DAB Chromogenic Substrate Kit for staining tissue sections. The solution should remain clear, colorless, without precipitates. The 4% Paraformaldehyde solution should not be used in PBS.